Results 61 to 70 of about 2,703,409 (308)

Post-Neoadjuvant Treatment in HER2-Positive Breast Cancer: Escalation and De-Escalation Strategies

, 2022
SIMPLE SUMMARY: The response to neoadjuvant treatment is strongly associated with the clinical outcome of breast cancer patients, especially in the HER2-positive subtype of the disease.
Lars Hanker, Achim Rody, Fehm, Tanja, Maggie Banys-Paluchowski, Tanja Fehm, Laura Brus, Kopperschmidt, Valeria, Hanker, Lars, Brus, Laura, Eugen Ruckhaeberle, Krawczyk, Natalia, Rody, Achim, Natalia Krawczyk, Valeria Kopperschmidt, Ruckhaeberle, Eugen, Banys-Paluchowski, Maggie   +15 more
core   +1 more source

Reprogramming tumor cells with LCOR mRNA nanotherapy to enhance immunotherapy

Molecular Oncology, EarlyView.
LCOR (Ligand‐dependent corepressor) mRNA encapsulated in polymeric nanoparticles restores LCOR activity in tumor cells, constraining aggressive tumor cell states and increasing tumor immunogenicity. This reprogramming makes tumor cells more vulnerable to T‐cell attack and enhances their response to immune‐checkpoint immunotherapy.
Gabriel Serra‐Mir, Elena Haro‐Martínez, Sandra Blasco‐Benito, Chiara Cannatà, José Ángel Palomeque, Anna López‐Plana, Maria Sanz‐Flores, Marc Sabartés, Cristina Fornaguera, Toni Celià‐Terrassa   +9 more
wiley   +1 more source

Overcoming platinum resistance by the disulfiram metabolite CuET in novel preclinical models of human carcinomas

Molecular Oncology, EarlyView.
Cisplatin‐resistant cancer cells survive DNA‐damaging platinum‐based treatment yet remain sensitive to CuET‐induced proteotoxic stress. The distinct mechanism of action allows CuET to overcome and eliminate cisplatin‐resistant tumour cells, unless highly expressed metallothioneins (MTs) interfere with CuET, thereby highlighting MT levels as candidate ...
Stefanos Arampatzis, Tereza Buchtová, Jirina Bartkova, Marie Lund Bay, Christoffer Lynge Halvorsen, Zuzana Machacova, Zdenek Skrott, Martin Mistrik, Ekaterina Dulina, Miguel Andujar‐Sanchez, Estrid Høgdall, Tine Henrichsen Schnack, Claus Høgdall, Berit Jul Mosgaard, Marie Boennelycke, Jacob Brink Laursen, Allan Jensen, Susanne K. Kjær, Tuula Kallunki, Robert Strauss, Jiri Bartek   +20 more
wiley   +1 more source

Current Status of Immunotherapy in Neoadjuvant Therapy for Gastric Cancer

Zhongliu Fangzhi Yanjiu, 2022
The majority of diagnosed cases of gastric cancer are in the middle and late stages, while less than 10% of patients are diagnosed in the early stages in China.
CHEN Bojin, HU Xingyi, ZHAO Jingwen, ZHENG Aihong   +3 more
doaj   +1 more source

Five‐Year Outcomes of Laparoscopic Sphincter‐Preserving Surgery for Rectal Cancer: A Prospective Study in Elderly Vietnamese Patients

Aging and Cancer, EarlyView.
This prospective study demonstrates that laparoscopic sphincter‐preserving surgery is feasible for elderly patients. While overall survival reaches 70% at 5 years, advanced T‐stage and the omission of neoadjuvant therapy significantly drive recurrence, highlighting the need for personalized geriatric protocols despite logistical challenges.
Huu Duc Ho, Quang Le, Ngoc Thach Tran, Van Viet Ung, Loc Vu   +4 more
wiley   +1 more source

Study on pathological factors affecting the sensitivity of neoadjuvant therapy in hypopharyngeal cancer

Cancer Immunology, Immunotherapy
Objective Hypopharyngeal squamous cell carcinoma (HSCC) is a highly malignant tumor type in the head and neck region. In recent years, neoadjuvant therapy has significantly improved the laryngeal preservation rate among patients.
Gaofei Yin, Nuan Li, Xiaohong Chen, Yang Zhang, Zhigang Huang, Wei Guo   +5 more
doaj   +1 more source

Dual Role of Tamoxifen in Enhancing STING and CEACAM1 Expression to Prime a Favorable Tumor Microenvironment for Anti‐TIM3 Immunotherapy

Advanced Science, EarlyView.
Anti‐PD‐1/PD‐L1 blockade has revolutionized cancer immunotherapy, but is ineffective against endocrine‐treated (i.e., Tamoxifen), relapsed ER+ breast cancer (BC) patients. This study provides insight into the sub‐optimal response of ER+BCs to anti‐PD‐1/PD‐L1 blockade – highlighting the induction of STING and the CEACAM1/TIM3 axis after chronic ...
Marvin Angelo E Aberin, Saurabh Singh, Soumya Chatterjee, Guang‐Zhi Sui, Yi‐Fu Wang, Ya‐Ting Lu, Yu‐Ling Lee, Kun‐Yuan Lin, Joy Khag, Ta‐Yu Liu, Shao‐Han Chang, Wai‐Mui Cheung, Hsiao‐Chin Hong, Ren‐Jun Hsu, Chen‐Yang Shen, Chia‐Wei Li, Weng‐Lang Yang, Yao‐Ming Chang, Shih‐Yu Chen, Chandan Guha, Shu‐Ping Wang   +20 more
wiley   +1 more source

Neoadjuvant therapy demonstrates both safety and clinical feasibility for renal cell carcinoma patients with tumor thrombus

Discover Oncology
Background While the applications of neoadjuvant therapies on patients diagnosed with renal cell carcinoma (RCC) with tumor thrombus (TT) is growing, the safety of preoperative therapies has yet to be clarified.
Le Yu, Kewei Chen, Liyuan Ge, Fan Zhang, Shaohui Deng, Jianfei Ye, Ye Yan, Guoliang Wang, Shudong Zhang   +8 more
doaj   +1 more source

Longitudinal Morphomolecular Monitoring of Head and Neck Carcinogenesis

Advanced Science, EarlyView.
A miniaturized endoscopic probe that integrates Raman spectroscopy and optical coherence tomography, enabling simultaneous molecular and structural imaging of living tissue, was developed. Applied longitudinally in a mouse model of head and neck cancer, the system tracks disease progression from precancerous lesions to invasive cancer.
Jianrong Qiu, Priyanka G. Bhosale, Vishal Kumar, Jeyrroy Gabriel, Shiyue Liu, Ciro Chiappini, Richard J. Cook, Mads S. Bergholt   +7 more
wiley   +1 more source

Advances in the use of Radiomics and Pathomics for predicting the efficacy of neoadjuvant therapy in tumors

Translational Oncology
Neoadjuvant therapy is widely used for treating malignant tumors, but its efficacy varies among patients. Currently, tools or biomarkers for early and accurate evaluation of the efficacy of neoadjuvant therapy are lacking.
Jiayi Wang, Jiahui Dai, Yangxi Cheng, Xirui Wang, Rui Deng, Huiyong Zhu   +5 more
doaj   +1 more source